

UNCLASSIFIED

AD NUMBER
ADB282776
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 2001. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 28 July 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9460

TITLE: Mechanisms and Components of the DNA Damage Checkpoint

PRINCIPAL INVESTIGATOR: Marc F. Schwartz
Dr. David Stern

CONTRACTING ORGANIZATION: Yale University
New Haven, Connecticut 06510

REPORT DATE: September 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Sep 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20021001 104

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9460
Organization: Yale University

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Carol B. Christian

6/5/02

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)**2. REPORT DATE**

September 2001

3. REPORT TYPE AND DATES COVERED

Annual Summary (1 Sep 00 - 31 Aug 01)

4. TITLE AND SUBTITLE

Mechanisms and Components of the DNA Damage Checkpoint

5. FUNDING NUMBERS

DAMD17-99-1-9460

6. AUTHOR(S)Marc F. Schwartz
Dr. David Stern**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**Yale University
New Haven, Connecticut 06510

E-mail: marc.f.schwartz@yale.edu

**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Distribution authorized to U.S. Government agencies only (proprietary information, Sep 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

Survival of genotoxic stress is essential to the survival of any organism. The DNA damage checkpoint (DDC) is a regulatory system that controls the cellular response to DNA damage. Dysfunction of components of the mammalian DDC, such as ATM, hChk2, p53, and BRCA1, correlates with increased cancer risk. DDC mechanisms are conserved; in *Saccharomyces cerevisiae*, ATM-family kinase *MEC1* is required for the DDC, as are hChk2-homolog Rad53 and BRCA1-like Rad9. The powerful genetic and biochemical techniques available in the *S. cerevisiae* system present it as an ideal model organism in which to study the conserved DDC mechanisms.

Mec1-dependent phosphorylation of Rad53 correlates with the propagation of the DDC signal. Mec1 is also required for the DDC-dependent phosphorylation of Rad9, and Rad53 interacts with phosphorylated Rad9, suggesting that Rad9 acts as an adaptor for the DDC signaling pathway. A goal of this work is to characterize physical and catalytic interactions between Mec1, Rad53, and Rad9. As reported herein, I determined the contribution of Mec1 consensus phosphorylation sites within Rad9 to the functions of Rad9 in the regulation of Rad53 and the DNA damage checkpoint pathway. Further, I demonstrated the direct binding of Rad53 FHA domains to phosphorylated Rad9 peptide *in vitro*.

14. SUBJECT TERMS

DNA Damage Checkpoint, MEC1, RAD53, RAD9, FHA domain

15. NUMBER OF PAGES

12

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6
Appendices (Figures).....	9

Introduction

Survival of genotoxic shock is essential to the survival of any organism. The DNA damage checkpoint (DDC) controls the cellular response to DNA damage (10, 19, 23, 24). Dysfunction of components of the mammalian DDC, such as ATM, hChk2, p53, and BRCA1, correlates with accelerated tumorigenesis, increased cancer risk, and tumor chemotherapeutic resistance (2, 8, 11, 18, 20, 21). Eukaryotic DDC mechanisms are conserved; in *Saccharomyces cerevisiae*, ATM-family kinase *MEC1* is required for the DDC, as are Rad53 and Rad9 (1, 5, 12, 14, 16, 19, 22, 25, 29, 30, 31). Rad53 is the founding member of a kinase family implicated in DDCs, including mammalian homolog hChk2 (3, 4, 12, 13, 15, 30). Rad9 shares homology with the BRCA1 C-terminus (32). *S. cerevisiae* thus provides a powerful genetic system in which to study the conserved DDC mechanisms.

The Mec1-dependent phosphorylation of Rad53 correlates with the propagation of the DDC signal (17, 26, 27). Mec1 is also required for the DDC-dependent phosphorylation of Rad9 (26, 7, 28), leading to the binding of Rad53 to phospho-Rad9 via the FHA domains of Rad53 (26, 6). The two objectives of this project are: to define the molecular and catalytic interaction between Mec1, Rad53, and Rad9 that lead to the activation of Rad53 by the DDC; and to identify and begin characterization of mammalian homologs of *RAD53*. As I reported last year, the second objective was completed and published by multiple independent laboratories within the first year of my project. In the past year, I focused my time on detailed experiments within the later two tasks of my first objective, namely a detailed analysis of the interaction of Rad53 with Mec1 phosphorylation sites within Rad9.

Progress on Objective 1: Characterization of physical and catalytic interactions of Mec1

Task 3: characterization of physical interactions between Mec1, Rad53, and Rad9

To characterize the formation of a complex including Mec1, Rad53, and Rad9, I sought to identify by immunoprecipitation a complex containing Mec1 and Rad9 or Rad53. Despite repeated attempts by myself and other members of the laboratory, we have been unable to coimmunoprecipitate such a complex. Genetic and biochemical data, however, indicates that Rad9 is likely a direct substrate of Mec1 *in vivo*, and, as I reported from my studies last year, Mec1 phosphorylates an ATM-family consensus [S/T]Q site within Rad9 *in vitro*. To expand our understanding of the Rad53-Rad9 interaction first discovered in our laboratory, I studied the possibility that the putative Mec1 phosphorylation [S/T]Q sites within Rad9 are *bona fide* DNA damage-induced phosphorylation sites that serve as Rad53 FHA domain docking sites *in vivo*. This is especially exciting as, though the FHA domain is a novel phosphorylation-dependent protein binding domain with several literature reports of *in vitro* binding specificities, not one *in vivo* FHA domain binding site has yet been described.

As I reported last year, mutagenesis of [S/T]Q sites within Rad9 determined that a [S/T]Q cluster domain (SCD) within Rad9 is required for the DDC-induced Rad9 phosphorylation and interaction of Rad9 with Rad53. The Rad9 SCD contains a total of six [S/T]Q sites. To determine if a single site has a dominant contribution to Rad9 phosphorylation and interaction with Rad53, I tested a series of *rad9* mutants containing single alanine substitutions of individual SCD sites. Mutation of single [S/T]Q sites within the SCD had little apparent effect on the DNA damage induced phosphorylation of Rad9, immunoprecipitation of Rad9 with Rad53, or Rad53 phosphorylation (Figure 1). Since simultaneous substitution of all six sites does inactivate these functions, these data suggest that there are multiple phosphorylation sites within this group, and that Rad53 interacts redundantly with some or all of these sites.

To characterize the ability of a single Rad9 SCD site to support the interaction of Rad9 with Rad53, I examined the rescue of Rad9 and Rad53 DNA damage checkpoint regulation after restoration of single [S/T]Q residues into an otherwise mutant SCD. Reintroduction of a wildtype residue at Rad9 S435 best restored the DNA damage-induced slower mobility forms of Rad9 (Figure 2). However, reintroduction of Rad9 S435 only modestly rescued the DNA damage-induced Rad9 coimmunoprecipitation with Rad53, and the phosphorylation of Rad53 (Figure 2). By contrast, reintroduction of Rad9 T390 moderately restored the DNA damage-induced slower mobility forms of both Rad9 and Rad53 (Figure 2). However, even this add-back mutant only partially

rescued coimmunoprecipitation of Rad9 with Rad53, and no single Rad9 cluster add-back allele fully restored the checkpoint-induced phosphorylation or coimmunoprecipitation of Rad9 and Rad53 (Figure 2). These data indicate that the Rad9 [S/T]Q cluster sites may act in an additive or cooperative manner to recruit Rad53. Moreover, these results extend the absolute correlation between the ability of Rad9 to coimmunoprecipitate with Rad53 and the damage-regulated phosphorylation of Rad53, supporting the model that Rad9 functions as an adaptor for the DDC signaling pathway.

I also explored the impact of Rad9 SCD mutations on the function of the G₂/M arrest induced by the DDC (9). My analysis of the G₂/M DDC in wildtype, *rad9^{6xA}*, *rad9Δ*, and *rad53^{FHA2-NVS}* demonstrated that *rad9^{6xA}* has defects similar to those of the *rad53* cells (Figure 3). Consistent with the ability of the T390 add-back mutant to significantly recover the DNA damage-induced interaction of Rad9 with Rad53, reintroduction of Rad9 T390 to *rad9^{6xA}* also partially recovered the *RAD53*-dependent G₂/M arrest (Figure 3). However, this rescue was weak, suggesting that the regulation of Rad53 via an intact Rad9 SCD is required for the full action of the *RAD53*-dependent G₂/M DNA damage checkpoint arrest. Readdition of S435 to the *rad9^{6xA}* mutant only weakly recovering the coimmunoprecipitation of Rad9 with Rad53, was less able to recover the G₂/M arrest (Figure 3).

Survival of genotoxic stress requires the activity of the DNA checkpoint pathways, as well as the DNA repair systems. An understanding of this process is essential for the efficacious use of chemo- and radiotherapy. In *S. cerevisiae*, loss of *RAD9* impairs both the DNA damage checkpoint pathway and DNA repair, and significantly decreases the viability of cells challenged with DNA damage. Mutation of the Rad9 SCD (*rad9^{6xA}*) causes a very slight reduction in survival of DNA damage, which, like the *RAD9*-dependent phosphorylation of Rad53 in this mutant, is largely recovered by the restoration of a wildtype residue at T390 (Figure 4A). The additional mutation of another [S/T]Q site at T603 (*rad9^{7xA}*) cells causes a greater loss of viability (Figure 4A).

Tof1 was identified in a yeast two-hybrid screen with DNA topoisomerase I, and is required for the activation of Rad53 by the *RAD9*-independent DNA replication checkpoint pathway (33, 34). Inhibition of replication with hydroxyurea (HU) in DNA replication checkpoint mutants, such as *tof1Δ*, is thought to cause replication forks collapse, causing DNA damage (35, 36). Indeed, the deletion of *TOF1* causes HU-induced Rad53 phosphorylation to be *RAD9*-dependent (34). Therefore, I determined whether the *rad9^{7xA}* mutation decreases the HU survival of a *tof1Δ* mutant. Wildtype, *tof1Δ*, and *rad9^{7xA}* strains are similarly viable when grown on HU-containing media, whereas the *tof1Δ rad9^{7xA}* double mutant is very sensitive to growth on HU (Figure 4B). The *tof1Δ rad53Δ* mutant is more sensitive to HU than the *tof1Δ rad9^{7xA}* mutant (Figure 5B), suggesting that even if Rad53 activation is compromised, Rad53 still contributes to the survival of DNA damage. Notably, a *rad53Δ* background uncovers a more significant loss of HU survival upon *TOF1* deletion than normally observed in a wildtype background (Figure 4B).

In addition to interacting with and thereby regulating the phosphorylation of Rad53, Rad9 also regulates the phosphorylation of another DDC component, Chk1. I am currently examining whether Rad9 SCD mutants that are defective for Rad53 regulation are similarly impaired for Chk1 regulation. I am also developing a method to purify *in vivo* phosphorylated Rad9 from yeast cell lysates, in order to directly identify Rad9 phosphorylation sites by mass spectroscopy.

Task 4: *in vitro* reconstruction of the Rad53-Rad9 interaction

One of the outstanding questions about the Rad53-Rad9 interaction is whether the interaction is direct, or via another polypeptide or other intermediary. To distinguish these possibilities, I sought to demonstrate Rad53 binding to Rad9 *in vitro* using components generated independent of *S. cerevisiae*. The ability of Rad9^{6xA+T390} to enable a significant proportion of the Rad9 interaction with Rad53 implies that T390 is a major functional site for Rad53 binding *in vivo*. To determine if Rad53 binds directly to Rad9 T390 in a phosphorylation-dependent manner, I measured the increase of surface plasmon resonance caused by binding of soluble, bacterially produced Rad53 FHA domains to synthetic Rad9 T390 peptides immobilized on a BIAcore

sensor chip. Rad53 FHA1 specifically interacted with the phosphorylated Rad9 T390 peptide (*P*-T390), and mutation of two conserved FHA domain residues abolished this binding (Figure 5). Similar to FHA1, GST-Rad53 FHA2 preferentially bound the phosphorylated Rad9 T390 peptide, demonstrating an affinity lost upon mutation of conserved FHA2 residues (Figure 5). On average, Rad53 FHA1 bound the phosphorylated Rad9 T390 peptide with a K_D of 2.5 μ M ($s=0.3$, $n=6$), and GST-Rad53 FHA2 bound with a K_D of 1.4 μ M ($s=0.3$, $n=3$), though the observed affinity of GST-FHA2 may have been artificially increased due to the ability of GST to homodimerize. Taken together, these results show that the Rad53 FHA domains can directly and specifically bind Rad9 peptides phosphorylated at ATM-family consensus [S/T]Q phosphorylation sites.

Key Research Accomplishments

- Characterized the contribution of the Rad9 SCD to
 - Rad9 phosphorylation
 - Interaction of Rad9 with Rad53
 - Rad53 phosphorylation
 - Function of the G2/M DNA damage checkpoint arrest
 - Survival of genotoxic stress
- Demonstrated *in vitro* the direct binding of Rad53 FHA domains to a phosphorylated Rad9 SCD peptide

Reportable Outcomes

1. Manuscripts, abstracts, and presentations
2. Patents and licenses applied for and/or issued
3. Degrees obtained
4. Development of cell lines, tissue or serum repositories
5. Informatics
6. Funding applied for
7. Employment or research opportunities applied for

Summary

Significant progress has been made in meeting the goals of the first objective of this proposal. I identified a cluster of putative Mec1 phosphorylation sites within Rad9 that are required for the phosphorylation of Rad9, the interaction of Rad53 with Rad9, and the survival of genotoxic stress. I determined the contribution of individual sites within this cluster to the function of Rad9 in regulating Rad53 and the G2/M DNA damage checkpoint. I demonstrated that both Rad53 FHA domains bind a Rad9 SCD site *in vitro* when phosphorylated. I am exploring whether the Rad9 SCD contributes to Rad9 activities other than regulation of Rad53, and am seeking direct biochemical evidence that sites within the Rad9 SCD are phosphorylated in response to DNA damage. I am preparing a manuscript describing these results, and will be submitting it to a leading journal shortly.

References

1. Allen, J. B., Zhou, Z., Siede, W., Friedberg, E. C., and Elledge, S. J. (1994). The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. *Genes Dev.* 8, 2416-2428.
2. Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B., and Wang, J. Y. J. (1997). Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. *Nature* 387, 516-519.
3. Blasina, A., Weyer, de I. V., Laus, M. C., Luyten, W. H., Parker, A. E., and McGowan, C. H. (1999) A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. *Curr. Biol.* 9, 1-10.

4. Brown, A. L., Lee, C. H., Schwarz, J. K., Mitiku, N., Piwnica-Worms, H., and Chung, J.H. (1999) A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc. Natl. Acad. Sci.* 96, 3745-3750.
5. de la Torre-Ruiz, M. A., Green, C. M., and Lowndes, N. F. (1998). Rad9 and Rad24 define two additive, interacting branches of the DNA damage checkpoint pathway in budding yeast normally required for Rad53 modification and activation. *EMBO J.* 17, 2687-2698.
6. Durocher, D., Henckel, J., Fersht, A. R., and Jackson, S. P. (1999) The FHA domain is a modular phosphopeptide recognition motif. *Mol. Cell* 4, 387-394.
7. Emili, A., and Hartwell, L. H. (1998). MEC1-dependent phosphorylation of Rad9p in response to DNA damage. *Mol Cell* 2, 183-189.
8. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Changclaude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A. J., Gayther, S. A., Birch, J. M., Lindblom, A., *et al.* (1998). Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. *Am. J. Hum. Genet.* 62, 676-689.
9. Gardner, R., Putnam, C.W., and Weinert, T. (1999) RAD53, DUN1 and PDS1 define two parallel G2/M checkpoint pathways in budding yeast. *EMBO J* 18, 3173-85.
10. Hartwell, L. H., and Weinert, T. A. (1989). Checkpoints: controls that ensure the order of cell cycle events. *Science* 246, 629-634.
11. Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R., and Koi, M. (1995). Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. *Cancer Res.* 55, 3721-3725.
12. Kato, R., and Ogawa, H. (1994). An essential gene, *ESR1*, is required for mitotic cell growth, DNA repair, and meiotic recombination in *Saccharomyces cerevisiae*. *Nucleic Acids Res.* 22, 3104-3112.
13. Kiser, G. L., and Weinert, T. A. (1996). Distinct roles of yeast *MEC* and *RAD* checkpoint genes in transcriptional induction after DNA damage and implications for function. *Mol. Biol. Cell* 7, 703-718.
14. Lydall, D., and Weinert, T. (1995). Yeast checkpoint genes in DNA damage processing: implications for repair and arrest. *Science* 270, 1488-1491.
15. Matsuoka, S., Huang, M., and Elledge, S. J. (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science* 282, 1893-1897.
16. Paulovich, A. G., Margulies, R. U., Garvik, B. M., and Hartwell, L. H. (1997). *RAD9*, *RAD17*, and *RAD24* are required for S phase regulation in *Saccharomyces cerevisiae* in response to DNA damage. *Genetics* 145, 45-62.
17. Sanchez, Y., Desany, B. A., Jones, W. J., Liu, Q., Wang, B., and Elledge, S. J. (1996). Regulation of *RAD53* by the *ATM*-like kinases *MEC1* and *TEL1* in yeast cell cycle checkpoint pathways. *Science* 271, 357-359.
18. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G. J., Malcolm, A., Taylor, R., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S., and Shiloh, Y. (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 268, 1749-1753.
19. Schiestl, R. H., Reynolds, P., Prakash, S., and Prakash, L. (1989). Cloning and sequence analysis of the *Saccharomyces cerevisiae RAD9* gene and further evidence that its product is required for cell cycle arrest induced by DNA damage. *Mol. Cell. Biol.* 9, 1882-1896.
20. Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. (1997). Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell* 90, 425-435.
21. Sherr, C. J. (1996). Cancer cell cycles. *Science* 274, 1672-1677.

22. Siede, W., Friedberg, A. S., Dianova, I., and Friedberg, E. C. (1994). Characterization of the G₁ checkpoint control in yeast *Saccharomyces cerevisiae* following exposure to DNA-damaging agents. *Genetics* 138, 271-281.
23. Siede, W., Friedberg, A. S., and Friedberg, E. C. (1993). *RAD9* dependent G₁ arrest defines a second checkpoint for damaged DNA in the cell cycle of *Saccharomyces cerevisiae*. *Proc.Natl.Acad.Sci.* 90, 7985-7989.
24. Slater, M. L. (1973). Effect of reversible inhibition of deoxyribonucleic acid synthesis on the yeast cell cycle. *J. Bacteriol.* 113, 263-270.
25. Stern, D. F., Zheng, P., Beidler, D. R., and Zerillo, C. (1991). Spk1, a new kinase from *S. cerevisiae*, phosphorylates proteins on serine, threonine, and tyrosine. *Mol. Cell. Biol.* 11, 987-1001.
26. Sun, Z., Hsiao, J., Fay, D. S., and Stern, D. F. (1998). Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint. *Science* 281, 272-274.
27. Sun, Z., Fay, D. S., Marini, F., Foiani, M., and Stern, D. F. (1996). Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways. *Genes & Dev.* 10, 395-406.
28. Vialard, J. E., Gilbert, C. S., Green, C. M., and Lowndes, N. F. (1998) The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tell1-dependent hyperphosphorylation and interacts with Rad53 after DNA damage. *EMBO J.* 17, 5679-5688.
29. Weinert, T. A., and Hartwell, L. H. (1988). The *RAD9* gene controls the cell cycle response to DNA damage in *Saccharomyces cerevisiae*. *Science* 241, 317-322.
30. Weinert, T. A., Kiser, F. L., and Hartwell, L. H. (1994). Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. *Genes Dev.* 8, 652-665.
31. Zhou, Z., and Elledge, S. J. (1993). *DUN1* encodes a protein kinase that controls the DNA damage response in yeast. *Cell* 75, 1119-1127.
32. Koonin, E. V., Altschul, S. F., and Bork, P. (1996). BRCA1 protein products: functional motifs. *Nature Genetics* 13, 266-268.
33. Park, H. and R. Sternglanz. (1999) Identification and characterization of the genes for two topoisomerase I-interacting proteins from *Saccharomyces cerevisiae*. *Yeast* 15, 35-41.
34. Foss, E. (2001). Tof1p Regulates DNA Damage Responses During S Phase in *Saccharomyces cerevisiae*. *Genetics* 157, 567-77.
35. Tercero, J.A. and J.F. Diffley. (2001) Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. *Nature* 412, 553-7.
36. Lopes, M., Cotta-Ramusino, C., Pellicoli, A., Liberi, G., Plevani, P., Muzi-Falconi, M., Newlon, C. S., and Foiani, M. (2001) The DNA replication checkpoint response stabilizes stalled replication forks. *Nature* 412, 557-61.

Figures




Figure 1: Mutagenesis of the Rad9 SCD: 1. Single site mutations. Wildtype Rad9 (wt), an all-alanine SCD mutant (6xA), and single alanine substitutions of SCD sites were immunoprecipitated anti-Rad9 (top) or anti-Rad53 (middle) and blotted anti-HA (top and middle). Corresponding lysates (50 μ g) were blotted anti-Rad53 (bottom).




Figure 2: Mutagenesis of the Rad9 SCD: 2. Single wildtype sites in a multiple-alanine mutant SCD. Wildtype Rad9 (wt), all-alanine SCD mutants (6xA and 7xA), and multiple alanine SCD mutants with a single wildtype residue at the indicated site were immunoprecipitated anti-Rad9 (top) or anti-Rad53 (middle) and blotted with anti-HA (top and middle). Corresponding lysates (50μg) were blotted anti-Rad53 (bottom).




Figure 3: Mutation of the Rad9 SCD impairs the DNA damage checkpoint arrest at G₂/M. The ability of Rad9 SCD mutations to arrest as pre-anaphase cells at the G₂/M checkpoint arrest in response to DNA damage was compared to the known mutations in the DDC.




Figure 4: Rad9 SCD mutations impair the survival of DNA damage. Mutation of [S/T]Q sites within Rad9 reduce the viability of cells exposed to UV irradiation (top) and *tof1Δ* cells exposed to HU (bottom).




Figure 5: Surface plasmon resonance measurements of Rad53 FHA domains binding a Rad9 SCD peptide. Bacterially produced Rad53 FHA domain fusion proteins were flowed over the surface of a BIAcore sensor chip coated with the indicated Rad9 SCD site T390 peptide. Binding of the fusion proteins to the surface of the sensor chip is indicated by an increase of the surface plasmon resonance.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
534 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

28 July 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB233865	ADB264750
ADB265530	ADB282776
ADB244706	ADB286264
ADB285843	ADB260563
ADB240902	ADB277918
ADB264038	ADB286365
ADB285885	ADB275327
ADB274458	ADB286736
ADB285735	ADB286137
ADB286597	ADB286146
ADB285707	ADB286100
ADB274521	ADB286266
ADB259955	ADB286308
ADB274793	ADB285832
ADB285914	
ADB260288	
ADB254419	
ADB282347	
ADB286860	
ADB262052	
ADB286348	
ADB264839	
ADB275123	
ADB286590	
ADB264002	
ADB281670	
ADB281622	
ADB263720	
ADB285876	
ADB262660	
ADB282191	
ADB283518	
ADB285797	
ADB269339	
ADB264584	
ADB282777	
ADB286185	
ADB262261	
ADB282896	
ADB286247	
ADB286127	
ADB274629	
ADB284370	
ADB264652	
ADB281790	
ADB286578	